Last year (our 2005 edition), Pfizer was 47% ahead of its closest competitor in drug revenues ($46 billion to $31 billion), but that margin was shaved to 30% in 2005 as Pfizer sales dropped 4%. The company remains at #1 in our Top 20 Pharmaceutical rankings, with a $10 billion buffer between it and neck-and-neck competitors Sanofi-Aventis and GlaxoSmithKline, but for how long?
Roche posted the biggest dollar gains in 2005 revenues, up $2.8 billion (20%), thanks to a major contribution from Tamiflu (up $987 million in 2005).
At the lower end of our ranks, recent mergers in Japan have brought Astellas and Daiichi-Sankyo into the Top 20. Bayer’s acquisition of Schering AG will lead to another major jump next year, and more pressure placed on mid-tier firms.
Come to think of it, if a few of these “national champion” mergers come through—think GSK/AstraZeneca, and the long-anticipated Novartis/Roche combo—we could see a whole new lineup. . .
—Gil Y. Roth
Editor: Gil Y. Roth
Associate Editor: Kristin Brooks
Contributing Editor: Derek B. Lowe
Top 20 Pharmaceutical Companies
based on 2005 pharma revenues
|5||Johnson & Johnson||$22,322|
|6||Merck & Co.||$21,874|
|11||Eli Lilly & Co.||$13,781|